X4 Pharmaceuticals (NASDAQ:XFOR) Posts Quarterly Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) announced its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02, Zacks reports. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock traded up $0.07 during trading hours on Wednesday, hitting $3.24. 536,564 shares of the company traded hands, compared to its average volume of 641,872. X4 Pharmaceuticals has a 1-year low of $2.43 and a 1-year high of $4.83. The firm has a market cap of $321.25 million, a P/E ratio of -2.70 and a beta of 0.47. The firm’s 50-day simple moving average is $3.30 and its two-hundred day simple moving average is $3.79. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective for the company. Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 20th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Insider Activity

In other news, CFO David Kirske sold 11,767 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the completion of the transaction, the chief financial officer directly owned 155,983 shares in the company, valued at $446,111.38. This trade represents a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President John Volpone sold 24,576 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $109,117.44. Following the transaction, the president owned 265,305 shares in the company, valued at $1,177,954.20. This represents a 8.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 83,779 shares of company stock worth $353,387 over the last three months. Corporate insiders own 1.13% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.